CD274 and metastatic neoplasm: In addition to the role of anti-PD-1s as first line and in high expressing patients (PD-L1 >50%), the KeyNote042 study explored the effect of fixed-dose pembrolizumab 200 mg every 3 weeks in a less restrictive population that included treatment-naïve patients with metastatic disease and PD-L1 expression ≥1%.